A post-hoc analysis of the Prasinezumab trial in early Parkinson's disease

Dr. Gennaro Pagano discusses the findings of the post-hoc analysis of the PASADENA trial, a study using the monoclonal antibody Prasinezumab directed at aggregated α-synuclein, where motor progression trajectories differed between active and placebo groups. <a href="https://pubmed.ncbi.nlm.nih.gov/38622249/">Read article » </a>